ACOR Acorda Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACOR

Price (delayed)

$0.5482

Market cap

$13.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.34

Enterprise value

$141.58M

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults ...

Highlights
The company's EPS has surged by 66% YoY and by 51% QoQ
ACOR's net income is up by 38% QoQ and by 37% YoY
The company's equity fell by 38% YoY but it rose by 24% QoQ
The company's revenue fell by 8% YoY and by 4.4% QoQ
Acorda Therapeutics's gross profit has decreased by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.acorda.com
Peers: RGEN BMRN CHRS

Key stats

What are the main financial stats of ACOR
Market
Shares outstanding
24.34M
Market cap
$13.34M
Enterprise value
$141.58M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.14
Price to sales (P/S)
0.09
EV/EBIT
N/A
EV/EBITDA
5.1
EV/Sales
1.19
Earnings
Revenue
$118.57M
EBIT
-$5.05M
EBITDA
$27.76M
Free cash flow
-$21.06M
Per share
EPS
-$3.34
Free cash flow per share
-$1.07
Book value per share
$3.85
Revenue per share
$6.02
TBVPS
$4.59
Balance sheet
Total assets
$395.6M
Total liabilities
$301.97M
Debt
$172.92M
Equity
$93.62M
Working capital
$44.17M
Liquidity
Debt to equity
1.85
Current ratio
2.16
Quick ratio
1.54
Net debt/EBITDA
4.62
Margins
EBITDA margin
23.4%
Gross margin
74.4%
Net margin
-55.6%
Operating margin
-35.5%
Efficiency
Return on assets
-16.3%
Return on equity
-68.5%
Return on invested capital
-2.6%
Return on capital employed
-1.4%
Return on sales
-4.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACOR stock price

How has the Acorda Therapeutics stock price performed over time
Intraday
-3.82%
1 week
-14.99%
1 month
-40.86%
1 year
-68.85%
YTD
-28.5%
QTD
-28.5%

Financial performance

How have Acorda Therapeutics's revenue and profit performed over time
Revenue
$118.57M
Gross profit
$88.23M
Operating income
-$42.04M
Net income
-$65.92M
Gross margin
74.4%
Net margin
-55.6%
Acorda Therapeutics's operating income has increased by 46% YoY and by 18% QoQ
ACOR's operating margin is up by 41% year-on-year and by 14% since the previous quarter
ACOR's net income is up by 38% QoQ and by 37% YoY
Acorda Therapeutics's net margin has increased by 35% QoQ and by 31% YoY

Growth

What is Acorda Therapeutics's growth rate over time

Valuation

What is Acorda Therapeutics stock price valuation
P/E
N/A
P/B
0.14
P/S
0.09
EV/EBIT
N/A
EV/EBITDA
5.1
EV/Sales
1.19
The company's EPS has surged by 66% YoY and by 51% QoQ
ACOR's P/B is 77% below its 5-year quarterly average of 0.6 but 40% above its last 4 quarters average of 0.1
The company's equity fell by 38% YoY but it rose by 24% QoQ
ACOR's price to sales (P/S) is 87% lower than its 5-year quarterly average of 0.7 and 10% lower than its last 4 quarters average of 0.1
The company's revenue fell by 8% YoY and by 4.4% QoQ

Efficiency

How efficient is Acorda Therapeutics business performance
ACOR's ROIC has soared by 94% year-on-year and by 89% since the previous quarter
The company's return on sales has surged by 93% YoY and by 88% QoQ
Acorda Therapeutics's ROA has increased by 35% from the previous quarter and by 22% YoY
Acorda Therapeutics's ROE has increased by 28% from the previous quarter but it has decreased by 17% YoY

Dividends

What is ACOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACOR.

Financial health

How did Acorda Therapeutics financials performed over time
ACOR's total assets is 31% greater than its total liabilities
ACOR's quick ratio is up by 33% from the previous quarter
Acorda Therapeutics's current ratio has increased by 26% QoQ and by 14% YoY
Acorda Therapeutics's debt is 85% higher than its equity
Acorda Therapeutics's debt to equity has increased by 47% YoY but it has decreased by 28% from the previous quarter
The company's equity fell by 38% YoY but it rose by 24% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.